Janux Therapeutics Inc (JANX)
58.19
+1.19
(+2.09%)
USD |
NASDAQ |
May 01, 16:00
58.24
+0.05
(+0.09%)
After-Hours: 07:13
Janux Therapeutics Net Income (Quarterly): -11.76M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -11.76M |
September 30, 2023 | -11.57M |
June 30, 2023 | -17.51M |
March 31, 2023 | -17.46M |
December 31, 2022 | -16.06M |
September 30, 2022 | -16.70M |
June 30, 2022 | -16.89M |
March 31, 2022 | -13.41M |
Date | Value |
---|---|
December 31, 2021 | -13.42M |
September 30, 2021 | -10.77M |
June 30, 2021 | -6.206M |
March 31, 2021 | -2.284M |
December 31, 2020 | -1.655M |
September 30, 2020 | -1.256M |
June 30, 2020 | -2.46M |
March 31, 2020 | -1.413M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-17.51M
Minimum
Jun 2023
-1.256M
Maximum
Sep 2020
-10.05M
Average
-11.66M
Median
Net Income (Quarterly) Benchmarks
Viking Therapeutics Inc | -27.36M |
Equillium Inc | -2.342M |
Minerva Neurosciences Inc | -9.022M |
Arvinas Inc | -154.80M |
Calidi Biotherapeutics Inc | -8.229M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 2.461M |
Total Expenses (Quarterly) | 18.60M |
EPS Diluted (Quarterly) | -0.24 |
Enterprise Value | 2.662B |
Profit Margin (Quarterly) | -477.8% |
Earnings Yield | -2.29% |
Normalized Earnings Yield | -2.286 |